References of "REGINSTER, Jean-Yves"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailMeta-analysis of the effects of inhaled corticosteroids on bone in asthmatic and COPD patients
Richy, Florent; Bousquet, Jean; Devogelaer, Jean-Pierre et al

in Arthritis and Rheumatism (2002, September), 46(number 9 (suppl.)), 464

Detailed reference viewed: 2 (0 ULg)
Full Text
Peer Reviewed
See detailSubchondral tibial bone mineral density predicts joint space narrowing at the medial femoro-tibial compartment in patients with knee osteoarthritis
Bruyère, Olivier ULg; LAMBERT, Virginie ULg; Dardenne, Charles et al

in Arthritis and Rheumatism (2002, September), 16(number 9 (suppl.)), 154

Detailed reference viewed: 6 (0 ULg)
Full Text
Peer Reviewed
See detailClinical severity of knee osteoarthritis poorly predicts long-term radiographic outcomes
Bruyère, Olivier ULg; Ethgen, Olivier ULg; Lejeune, Eric ULg et al

in Arthritis and Rheumatism (2002, September), 46(number 9 (suppl.)), 153

Detailed reference viewed: 9 (5 ULg)
Full Text
Peer Reviewed
See detailBaseline measurement of urine pyridinoline and deoxypyridinoline is correlated with 3-year hip osteoarthritis progression
Bruyère, Olivier ULg; COLLETTE, Julien ULg; Lejeune, Eric ULg et al

in Arthritis and Rheumatism (2002, September), 46(number 9 (suppl.)), 149

Detailed reference viewed: 6 (1 ULg)
Full Text
Peer Reviewed
See detailEfficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: Four-year results from a randomized clinical trial
Delmas, P. D.; Ensrud, K. E.; Adachi, J. D. et al

in Journal of Clinical Endocrinology and Metabolism (2002), 87(8), 3609-3617

The Multiple Outcomes of Raloxifene Evaluation trial studied 7705 postmenopausal women with osteoporosis randomized to placebo, or raloxifene 60 or 120 mg/d [JAMA 282(1999):6371. This report assesses the ... [more ▼]

The Multiple Outcomes of Raloxifene Evaluation trial studied 7705 postmenopausal women with osteoporosis randomized to placebo, or raloxifene 60 or 120 mg/d [JAMA 282(1999):6371. This report assesses the efficacy of raloxifene on the long-term cumulative incidence new vertebral fractures through 4 yr. New vertebral fractures was assessed from radiographs taken at baseline, yr 2-4. The primary analysis was the cumulative incidence of new vertebral fractures through 4 yr. A posthoc analysis compared the vertebral fracture risk in yr 4 alone with that observed in the first 3 yr. The 4-yr cumulative relative risks (RR) for one or more new vertebral fractures were 0.64 [95% confidence interval (CI) 0.53, 0.761 with raloxifene 60 mg/d and 0.57 (95% CI 0.48, 0.69) with raloxifene 120 mg/d. In yr 4 alone, raloxifene 60 mg/d reduced the new vertebral fracture risk by 39% [RR 0.61 (95% CI 0.43,0.88)], which was not found to be significantly different from the RR observed in the first 3 yr in both raloxifene groups, irrespective of prevalent fracture status. The nonvertebral fracture risk was not significantly reduced [RR 0.93 (95% CI 0.81, 1.06)]. The safety profile after 4 yr was similar to that observed after 3 yr. Raloxifene 60 and 120 mg/d through 4 yr decreased the cumulative risk of new vertebral fractures in postmenopausal women with osteoporosis. The decreased vertebral fracture risk in yr 4 alone was not different from that observed in the first 3 yr. [less ▲]

Detailed reference viewed: 11 (0 ULg)
Full Text
Peer Reviewed
See detailRisk indices and osteoporosis screening: Scope and limits
Ben Sedrine, Wafa ULg; Reginster, Jean-Yves ULg

in Mayo Clinic Proceedings (2002), 77(7), 622-623

Detailed reference viewed: 6 (2 ULg)
Full Text
Peer Reviewed
See detailDevelopment and assessment of the Osteoporosis Index of Risk (OSIRIS) to facilitate selection of women for bone densitometry
Sedrine, W. B.; Chevallier, T.; Zegels, Brigitte ULg et al

in Gynecological Endocrinology : The Official Journal of the International Society of Gynecological Endocrinology (2002), 16(3), 245-250

A simple questionnaire would be useful to identify individuals most in need of bone mineral density (BMD) testing. We designed a new predictive model and risk assessment instrument based on an extensive ... [more ▼]

A simple questionnaire would be useful to identify individuals most in need of bone mineral density (BMD) testing. We designed a new predictive model and risk assessment instrument based on an extensive review of the literature evaluating risk factors for osteoporosis, and tested its performance in a large cohort of postmenopausal women in whom BMD was measured by dual x-ray absorptiometry. In total, 1303 postmenopausal women from an outpatient osteoporosis clinic participated in this study. The Osteoporosis Index of Risk (OSIRIS) is based on four variables: age, body weight, current hormone replacement therapy use and history of previous low impact fracture. The sensitivity and specificity for an OSIRIS value of +1 were respectively 78.5% and 51.4%. The AUC under the ROC curve of OSIRIS was 0.71. Three categories were arbitrarily created using OSIRIS, with cutoff of +1 and -3. The low risk category (OSIRIS > +1) represented 41% of all women; only 7% of the women in this category had osteoporosis. The prevalence of osteoporosis was very high (66%) among the group at high risk (OSIRIS < -3 representing 15% of all women). The prevalence of osteoporosis was 39% in the intermediate risk group (-3 < OSIRIS < +1, 44% of all women). In conclusion, OSIRIS is a simple index based on four easy-to-collect variables from postmenopausal women, it shows a high degree of accuracy, and performed well for classifying the degree of risk of osteoporosis in western European women of Caucasian lineage. Based on this instrument it is possible to propose a strategy that would initiate treatment in women with very high risk, postpone BMD measurement in women with low risk and limit BMD measurement to women with intermediate risk of osteoporosis, this would spare more than 55% of the densitometry bill compared with a mass screening scenario. [less ▲]

Detailed reference viewed: 10 (2 ULg)
Full Text
Peer Reviewed
See detailPain relief is not a confounder in joint space narrowing assessment of full extension knee radiographs
Pavelka, K.; Rovati, Lucio C; Gatterova, J. et al

in Annals of the Rheumatic Diseases (2002, June), 61(Suppl.1), 118

Detailed reference viewed: 16 (10 ULg)
Full Text
Peer Reviewed
See detailFirst clinical results of licofelone (ml3000), an inhibitor of COX-1, COX-2 and 5-LOX, for the treatment of osteoarthritis
Reginster, Jean-Yves ULg; Bias, P.; Buchner, A.

in Annals of the Rheumatic Diseases (2002, June), 61(Suppl.1),

Detailed reference viewed: 44 (6 ULg)
Full Text
Peer Reviewed
See detailOnce weekly alendronate produces a greater decrease in bone resorption than daily risedronate
Hosking, D.; Adami, Silvio; Felsenberg, D. et al

in Annals of the Rheumatic Diseases (2002, June), 61(Suppl.1),

Detailed reference viewed: 19 (9 ULg)
Full Text
Peer Reviewed
See detailReduction in vertebral fracture rates by a combination of monofluorophosphate and raloxifene in postmenopausal osteoporosis
Durez, P.; Felsenberg, D.; Stepan, J. et al

in Annals of the Rheumatic Diseases (2002, June), 61(Suppl.1),

Detailed reference viewed: 15 (7 ULg)
Full Text
Peer Reviewed
See detailRadiographic severity of knee osteoarthritis is highly correlated with future progression of the disease
Reginster, Jean-Yves ULg; Henrotin, Yves ULg; Bruyère, Olivier ULg et al

in Annals of the Rheumatic Diseases (2002, June), 61(Suppl.1), 124

Detailed reference viewed: 7 (4 ULg)
Full Text
Peer Reviewed
See detailInterest of a prescreening questionnaire to reduce the cost of bone densitometry
Ben Sedrine, Wafa ULg; Broers, P.; Devogelaer, J. P. et al

in Osteoporosis International (2002), 13(5), 434-442

Bone mineral density (BMD) measurement is widely recognized as the best single tool to identify patients with a high lifetime risk of developing an osteoporosis-related fracture. However, the cost/benefit ... [more ▼]

Bone mineral density (BMD) measurement is widely recognized as the best single tool to identify patients with a high lifetime risk of developing an osteoporosis-related fracture. However, the cost/benefit value of screening the whole population has been repeatedly challenged and demonstrated to be rather poor. In many countries, BMD scan is not or no longer reimbursed because of lack of validated criteria to identify patients who should benefit from this procedure. Based on the proposals of a nationwide expert panel, a simple questionnaire identifying historical, clinical and behavioral risk factors for osteoporosis was developed. The aim of this study was to assess the diagnostic accuracy of the proposed criteria; to determine the extent to which this questionnaire could be useful for optimizing the use of densitometry tests; and, more specifically, to estimate the diagnostic costs per osteoporotic or osteopenic patient detected. For this purpose, we applied the questionnaire to 3998 consecutive individuals at least 20 years old, of both genders, either consulting spontaneously or referred for a BMD measurement to an outpatient osteoporosis center. BMD was measured by dual-energy X-ray absorptiometry (DXA) at the lumbar spine and at the hip (both total hip and femoral neck). Diagnostic accuracies were evaluated through measures of sensitivity, specificity, and positive and negative predictive values. After determining a benchmark value for age, different strategies were compared in order to identify the most cost-effective one in terms of cost per patient detected. According to the WHO operational definition of osteoporosis (T-score <-2.5), 31% of the subjects were classified as osteoporotic at one or more of the measured sites. If only patients with at least one of the proposed risk factors had been referred for scans, 33.3% of the BMD measurements would have been avoided. Among those, less than 5% were missclassified as they did have osteoporosis at the total hip and up to 23% at one or more of the considered sites. On the other hand, of the subjects who would be recommended for a densitometry test, only a small fraction were identified correctly (the positive predictive values varied from 11.3% at the total hip to 34.8% at any site). In this first setting, the suggested criteria seem useful chiefly for excluding subjects who do not need a DXA scan rather than selecting osteoporotic patients. When applied only to patients aged 61 years or more, the positive predictive values rose to 15.1% (total hip) and 42.9% (any site), whereas the corresponding negative predictive values were set at 93% and 68.6%. In comparison, with a mass screening scenario the estimated diagnostic costs (costs associated with the DXA procedure) per osteoporotic patient detected at any of the considered sites would be reduced by more than 9% (59.4 instead of 65.3 Euros) if the suggested indications are taken into account for prescreening patients. And when the questionnaire is applied only to women over the age of 60 years these costs would be further reduced to 50.6 Euros, representing a 23% decrease. Then, a prescreening strategy based on these indications concomitantly with an age-selective criterion could represent a promising way toward a more rational use of BMD measurement. [less ▲]

Detailed reference viewed: 97 (1 ULg)
Full Text
Peer Reviewed
See detailStrontium ranelate: Dose-dependent effects in established postmenopausal vertebral osteoporosis - A 2-year randomized placebo controlled trial
Meunier, P. J.; Slosman, D. O.; Delmas, P. D. et al

in Journal of Clinical Endocrinology and Metabolism (2002), 87(5), 2060-2066

The aim of the strontium ranelate (SR) for treatment of osteoporosis (STRATOS) trial was to investigate the efficacy and safety of different doses of SR, a novel agent in the treatment of postmenopausal ... [more ▼]

The aim of the strontium ranelate (SR) for treatment of osteoporosis (STRATOS) trial was to investigate the efficacy and safety of different doses of SR, a novel agent in the treatment of postmenopausal osteoporosis. A randomized, multicenter, double-blind, placebo-controlled trial was undertaken in 353 osteoporotic women with at least one previous vertebral fracture and a lumbar T-score <-2.4. Patients were randomized to receive placebo, 0.5 g, 1 g, or 2 g SR/d for 2 yr. The primary efficacy endpoint was lumbar bone mineral density (BMD), assessed by dual-energy x-ray absorptiometry. Secondary outcome measures included femoral BMD, incidence of new vertebral deformities, and biochemical markers of bone metabolism. Lumbar BMD, adjusted for bone strontium content, increased in a dose-dependent manner in the intention-to-treat population: mean annual slope increased from 1.4% with 0.5 g/d SR to 3.0% with 2 g/d SR, which was significantly higher than placebo (P < 0.01). There was a significant reduction in the number of patients experiencing new vertebral deformities in the second year of treatment with 2 g/d SR [relative risk 0.56; 95% confidence interval (0.35; 0.89)]. In the 2 g/d group, there was a significant increase in serum levels of bone alkaline phosphatase, whereas urinary excretion of cross-linked N-telopeptide, a marker of bone resorption, was lower with SR than with placebo. All tested doses were well tolerated; the 2 g/d dose was considered to offer the best combination of efficacy and safety. In conclusion, SR therapy increased vertebral BMD and reduced the incidence of vertebral fractures. [less ▲]

Detailed reference viewed: 14 (1 ULg)
Full Text
Peer Reviewed
See detailMetabolism of human articular chondrocytes cultured in alginate beads. Longterm effects of interleukin 1 beta and nonsteroidal antiinflammatory drugs
Sanchez, Christelle ULg; Mateus, Marguarita; Defresne, Marie-Paule ULg et al

in Journal of Rheumatology (2002), 29(4), 772-782

OBJECTIVES: To investigate the longterm effects (12 days) of nonsteroidal antiinflammatory drugs [NSAID: aceclofenac (ACECLO), sodium diclofenac (DICLO), indomethacin (INDO), nimesulide (NIM), rofecoxib ... [more ▼]

OBJECTIVES: To investigate the longterm effects (12 days) of nonsteroidal antiinflammatory drugs [NSAID: aceclofenac (ACECLO), sodium diclofenac (DICLO), indomethacin (INDO), nimesulide (NIM), rofecoxib (ROFE), celecoxib (CELE), piroxicam (PIROX), and ibuprofen (IBUP)] on the metabolism of human chondrocytes cultured in alginate beads. METHODS: Enzymatically isolated osteoarthritic (OA) chondrocytes were cultured in alginate beads in a well defined culture medium for 12 days. The DNA content was measured according to a fluorimetric method and cell proliferation was determined by the incorporation of 3H-thymidine in the newly synthesized DNA. Interleukin 6 (IL-6) and IL-8, stromelysin [matrix metalloproteinase-3 (MMP-3)], and aggrecan (AGG) production were assayed by specific enzyme amplified sensitivity immunoassays, and prostaglandin E2 (PGE2) production by specific radioimmunoassay. All NSAID were tested at the mean peak plasma concentration (Cmax) obtained after oral administration of a therapeutic dose. RESULTS: In alginate beads, chondrocytes synthesized high amounts of AGG, which were largely (98%) immobilized in the alginate matrix. A large amount (43%) of the IL-8 produced was stored in the alginate beads, whereas almost all IL-6 production (94%) was released in the culture supernatant. At the therapeutic concentration, all NSAID tested fully blocked PGE2 production. ACECLO, DICLO, INDO, NIM significantly inhibited basal and IL-1beta stimulated IL-6 production; CELE and IBUP only inhibited IL-1beta stimulated IL-6 production; and ROFE and PIROX had no significant effects. No NSAID showed significant effects on basal and IL-1beta stimulated IL-8 production, except CELE and IBUP, which slightly increased basal IL-8 production. ACECLO and INDO increased AGG content by 25% in the alginate beads, while the other NSAID were without significant effect. No NSAID were able to modify the inhibitory effect of IL-1beta on AGG production. NSAID did not modify MMP-3 production. CONCLUSION: The mechanism of action of NSAID seems to be multifactorial and not limited to the inhibition of cyclooxygenases. Further, in our culture conditions, at the Cmax and by comparison with other NSAID, ACECLO and INDO show an advantageous activity profile. They fully blocked PGE2 production, inhibited IL-6 synthesis, and increased aggrecan synthesis. These effects appear advantageous for the longterm treatment of chronic joint diseases such as osteoarthritis. [less ▲]

Detailed reference viewed: 67 (5 ULg)
Full Text
Peer Reviewed
See detailThe prevalence and burden of arthritis
Reginster, Jean-Yves ULg

in Rheumatology (2002), 41(Suppl. 1), 3-7

The prevalence of arthritis is high, with osteoarthritis (OA) being one of the most frequent disorders in the population. In England and Wales, between 1.3 and 1.75 million people have OA and a further 0 ... [more ▼]

The prevalence of arthritis is high, with osteoarthritis (OA) being one of the most frequent disorders in the population. In England and Wales, between 1.3 and 1.75 million people have OA and a further 0.25 0.5 million have rheumatoid arthritis (RA), while in France some 6 million new diagnoses of OA Lire made each year. In 1997, similar to16%, of the US population had some form of arthritis. This prevalence is expected to increase in the coining years, as arthritis more often affects the elderly, a proportion of the population that is increasing. The economic burden of such musculoskeletal diseases is also high, accounting for up to 1-2.5%, of the gross national product of western nations. This burden comprises both the direct costs of medical interventions and indirect costs, such as premature mortality and chronic and short-term disability. The impact of arthritis on quality of life is of particular importance. Musculoskeletal disorders are associated with some of the poorest quality-of-life issues, particularly in terms of bodily pain (mean score from the MOS 36-item Short Form Health Survey of 52.1) and physical functioning (49.9), where quality of life is lower than that for gastrointestinal conditions (bodily pain 52.9, physical functioning 55.4), chronic respiratory diseases (72.7, 65.4) and cardiovascular conditions (64.7, 59.3). [less ▲]

Detailed reference viewed: 15 (1 ULg)